Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025

Krystal Biotech, Inc.

EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.
Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.
First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.